CV Health

Raising awareness on cardiology health

[Dr Rishabh Jain @DrRishabhOnco]

🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26

May 29 - June 2 | Chicago
Which trial are you watching most closely?

🌟 PLENARY GAME-CHANGERS

1️⃣ PROTEUS
Perioperative apalutamide + ADT in high-risk localized prostate cancer

2️⃣ LIBRETTO-432
Adjuvant selpercatinib in RET+ NSCLC

3️⃣ HARMONi-6
Ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC

4️⃣ RASolute 302
Daraxonrasib (RMC-6236) in metastatic pancreatic cancer

5️⃣ SARC041
Abemaciclib in dedifferentiated liposarcoma

⚡ FRONTLINE & PERIOPERATIVE SHIFTS

6️⃣ KEYNOTE-B15 / EV-304
EV + pembrolizumab vs chemo in MIBC

7️⃣ LITESPARK-022
Pembrolizumab + belzutifan in adjuvant ccRCC

8️⃣ AMBITION
Paclitaxel/bevacizumab ± atezolizumab in HR+ breast cancer

9️⃣ NeoADAURA
Neoadjuvant osimertinib in EGFR+ NSCLC

🔟 A-DREAM
ADT interruption strategies in mCSPC

🧬 PRECISION, ADCs & NEXT-GEN IMMUNOLOGY

1️⃣1️⃣ DESTINY-Breast06
T-DXd expands into HER2-ultralow disease

1️⃣2️⃣ CROWN (7-year update)
Lorlatinib durability in ALK+ NSCLC

1️⃣3️⃣ DeLLphi-312
Tarlatamab in frontline SCLC

1️⃣4️⃣ COMMIT
Atezolizumab + FOLFOX/Bev in MSI-H mCRC

1️⃣5️⃣ IMvigor011
ctDNA-guided adjuvant atezolizumab in bladder cancer

#OncoTwitter #MedTwitter #ASCO26 #CancerResearch @OncoAlert @ASCO @JCOPO_ASCO @OncBrothers

[CV Health @CV_HealthNews]

@yicaichina @Novartis @NovartisScience Thank you! What is the Chinese name?

[CV Health @CV_HealthNews]

CLEAR OUTCOMES https://t.co/asMO39mzjG

[CV Health @CV_HealthNews]

@SABOURETCardio Out of curiosity, will these data be enough for inclisiran's reimbursement France? Not sure if they need to wait for CV outcomes for long-term (3-4 years).

[Dr. Glaucomflecken @DGlaucomflecken]

An American experiences universal health care

[CV Health @CV_HealthNews]

@michaelgitter @Novartis Looks interesting. Haven't seen it before. Is it from a webinar?😄

[CV Health @CV_HealthNews]

@skathire Hi Dr. Kathiresan, thanks for sharing this data. It is indeed very interesting. Do you know how we know they are expected to reach >80% LDL-C reduction?

[CV Health @CV_HealthNews]

@youshizhiyu_ 你知道是在哪個國家的衛生部註冊為Sibrava嗎？之前的商品名稱好像是Leqvio.

[CV Health @CV_HealthNews]

@RheumNow Was it approved under priority review? It appears to have taken FDA only 6 months to review

[LipidLover MD @LipidLover1030]

Fantastic Kosh! Can’t wait to see your first published results! This shows us all in the US that it can be done easily and efficiently.

(Embrace this “oh all ye who treat LDL-C.”)

[John Kastelein @JohnKastelein]

@ProfKausikRay And you have a great job Kosh with all the meetings , consensus statements and bringing Europe together under the EAS banner ! #

[Prof Kausik Ray FMedSci @ProfKausikRay]

2021 was my first as EAS President, a tough year for everyone around the world. We innovated finding new ways to collaborate & continue our mission. Wishing everyone a safe and healthy holiday season and best for 2022 https://t.co/Ui3BspSBFP

[CV Health @CV_HealthNews]

@pash22 thoughts?

[CV Health @CV_HealthNews]

Will FDA approve inclisiran in the coming weeks, or will Novartis get another CRL based on the lack of a manufacturing facility inspection? @LipidLover1030 @DLBHATTMD @ProfKausikRay @lluismasana @JohnKastelein @FrederikRaal @lipiddoc

[Ash Paul @pash22]

@PCCS_UK @Hragy @AACinnovation Here's my tweetorial on Inclisiran ⬇️
https://t.co/KajHso9oZQ

[SEIS eSalud @SEISeSalud]

En el proyecto ANJANA se han identificado 7 líneas de mejora en la ruta asistencial dl paciente SCS en el ámbito #TIC. Este proyecto ha sido desarrollado por la #SEIS, junto con #AMGEN y un grupo de especialistas cardiólogos. Más información en https://t.co/xqMv2raDMv

[CV Health @CV_HealthNews]

@mi_cardiologo Hi Dr. Fácila, interesting presentation! Just curious about ORION-4's morbimortalidad data in Dec 2024, as the trial seems to complete in 2026. https://t.co/q8QJjT0wFt

[CV Health @CV_HealthNews]

Congratulations on this interesting overview!

[Stefania Di Fusco @doctstefania]

Proud to highlight/share the overview on the link between #lifestyle #CVD and #cancer with the contribution of amazing #youngcardiologists led by Prof. Colivicchi @ASLRoma1
https://t.co/qpGhKrEwSE
@CardioOncology @fikkumamoto @j_termeh @jstage_ej @CV_HealthNews @cardioncology

[Stefania Di Fusco @doctstefania]

Proud to highlight/share the overview on the link between #lifestyle #CVD and #cancer with the contribution of amazing #youngcardiologists led by Prof. Colivicchi @ASLRoma1
https://t.co/qpGhKrEwSE
@CardioOncology @fikkumamoto @j_termeh @jstage_ej @CV_HealthNews @cardioncology

[CV Health @CV_HealthNews]

@LipidLover1030 @drpablocorral Where did you hear a medical director from NVS mention a potential Lp(a) study? And were they referring to an Lp(a) study evaluating inclisiran or pelacarsen?